[go: up one dir, main page]

AR098908A1 - Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida - Google Patents

Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida

Info

Publication number
AR098908A1
AR098908A1 ARP140104850A ARP140104850A AR098908A1 AR 098908 A1 AR098908 A1 AR 098908A1 AR P140104850 A ARP140104850 A AR P140104850A AR P140104850 A ARP140104850 A AR P140104850A AR 098908 A1 AR098908 A1 AR 098908A1
Authority
AR
Argentina
Prior art keywords
methyl
hidroxifenil
octahidro
pirazino
bencil
Prior art date
Application number
ARP140104850A
Other languages
English (en)
Inventor
Inoue Satoshi
Yamamoto Yuji
Original Assignee
Eisai R&D Man Co Ltd
Prism Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Prism Pharma Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of AR098908A1 publication Critical patent/AR098908A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Un compuesto representado por la fórmula (1) o una sal farmacéuticamente aceptable de este: donde R¹ es un grupo alquilo C₁₋₆; R² y R³ son iguales o diferentes entre sí y cada uno es un átomo de hidrógeno o un grupo alquilo C₁₋₆; X², X³ y X⁴ son iguales o diferentes entre sí y cada uno es un átomo de hidrógeno o un átomo de halógeno; y X⁵ es un átomo de hidrógeno o -P(=O)(OH)₂, tiene una actividad de modulación de vía Wnt.
ARP140104850A 2013-12-25 2014-12-22 Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida AR098908A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013267687 2013-12-25

Publications (1)

Publication Number Publication Date
AR098908A1 true AR098908A1 (es) 2016-06-22

Family

ID=53399298

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104850A AR098908A1 (es) 2013-12-25 2014-12-22 Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida

Country Status (34)

Country Link
US (1) US9174998B2 (es)
EP (1) EP3088401B1 (es)
JP (1) JP6085040B2 (es)
KR (1) KR102307053B1 (es)
CN (1) CN105873932B (es)
AR (1) AR098908A1 (es)
AU (1) AU2014371148B2 (es)
BR (1) BR112016013572B1 (es)
CA (1) CA2932435C (es)
CL (1) CL2016001419A1 (es)
CY (1) CY1122521T1 (es)
DK (1) DK3088401T3 (es)
ES (1) ES2728353T3 (es)
HR (1) HRP20190908T1 (es)
HU (1) HUE044541T2 (es)
IL (1) IL245961A0 (es)
JO (1) JO3809B1 (es)
LT (1) LT3088401T (es)
ME (1) ME03391B (es)
MX (1) MX365376B (es)
MY (1) MY173946A (es)
PE (1) PE20160932A1 (es)
PH (1) PH12016501079A1 (es)
PL (1) PL3088401T3 (es)
PT (1) PT3088401T (es)
RS (1) RS58955B1 (es)
RU (1) RU2669805C2 (es)
SG (1) SG11201604496YA (es)
SI (1) SI3088401T1 (es)
SM (1) SMT201900306T1 (es)
TR (1) TR201908392T4 (es)
TW (1) TWI681961B (es)
UA (1) UA116923C2 (es)
WO (1) WO2015098853A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
LT3524595T (lt) 2014-08-28 2022-09-26 Eisai R&D Management Co., Ltd. Aukšto grynumo chinolino darinys ir jo gamybos būdas
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
MX373231B (es) * 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
KR102559211B1 (ko) * 2015-06-23 2023-07-25 에자이 알앤드디 매니지먼트 가부시키가이샤 (6S,9aS)-N-벤질-8-({6-[3-(4-에틸피페라진-1-일)아제티딘-1-일]피리딘-2-일}메틸)-6-(2-플루오로-4-하이드록시벤질)-4,7-디옥소-2-(프로프-2-엔-1-일)헥사하이드로-2H-피라지노[2,1-c][1,2,4]트리아진-1(6H)-카복사마이드의 결정
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
CN108084067B (zh) * 2016-11-22 2019-08-30 重庆圣华曦药业股份有限公司 一种立他司特中间体的制备方法
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
AU2020374883A1 (en) 2019-10-29 2022-05-26 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist, a VEGFR/FGFR/RET tyrosine kinase inhibitor and a CBP/beta-catenin inhibitor for treating cancer
JP7750851B2 (ja) 2020-03-12 2025-10-07 3+2 ファーマ リミテッド ライアビリティ カンパニー Cbp/カテニンシグナル伝達経路阻害薬およびそれらの使用
WO2021183791A1 (en) 2020-03-12 2021-09-16 City Of Hope Wnt/cbp/catenin signaling pathway inhibitors and uses thereof
EP4238567A4 (en) 2020-10-30 2024-09-04 Keio University NEW TREATMENT AND PREVENTION OF DISEASES RELATED TO SARCOPENIA
US20240352020A1 (en) * 2021-08-26 2024-10-24 3+2 Pharma, Llc Pyrazole-containing cbp/catenin antagonists and uses thereof
JP7445826B2 (ja) * 2021-09-08 2024-03-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 固形腫瘍治療用医薬組成物
CN116262120A (zh) * 2021-12-13 2023-06-16 上海中医药大学 特异性结合TRAF2的试剂在制备Wnt通路抑制剂中的应用
WO2023140369A1 (en) * 2022-01-18 2023-07-27 Prism BioLab Co., Ltd. Phosphoric acid derivatives
AU2023246216A1 (en) 2022-03-31 2024-09-19 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumors
CN115784934A (zh) * 2022-11-22 2023-03-14 上海吉奉生物科技有限公司 一种酪氨酸衍生物的合成方法
WO2024209717A1 (ja) 2023-04-06 2024-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
WO2025174646A1 (en) * 2024-02-12 2025-08-21 Albert Einstein College Of Medicine Inhibitors of beta-catenin c-terminal domain and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671054B1 (en) * 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
JP4387793B2 (ja) * 2001-10-12 2009-12-24 チョンウェ ファーマ コーポレーション 逆向ターンミメティックおよびそれに関連した方法
US8080657B2 (en) 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
AU2009255042B2 (en) 2008-06-06 2014-05-15 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto
RU2515983C2 (ru) * 2009-04-15 2014-05-20 Джей ДаблЮ ФАРМАСЬЮТИКАЛ КОРПОРЭЙШН Новые соединения миметиков обратного действия, способ их получения и применения
EP2628741B1 (en) 2010-10-14 2015-10-07 JW Pharmaceutical Corporation Novel compound of a reverse-turn mimetic and a production method and use therefor
EP2678341A1 (en) * 2011-02-25 2014-01-01 PRISM Pharma Co., Ltd. Alpha helix mimetics and methods relating thereto

Also Published As

Publication number Publication date
MX365376B (es) 2019-05-31
AU2014371148A1 (en) 2016-06-23
PT3088401T (pt) 2019-06-12
JPWO2015098853A1 (ja) 2017-03-23
SMT201900306T1 (it) 2019-07-11
RU2669805C2 (ru) 2018-10-16
US9174998B2 (en) 2015-11-03
HRP20190908T1 (hr) 2019-08-09
IL245961A0 (en) 2016-08-02
CA2932435C (en) 2021-08-17
SI3088401T1 (sl) 2019-08-30
LT3088401T (lt) 2019-07-25
PE20160932A1 (es) 2016-09-10
SG11201604496YA (en) 2016-07-28
MX2016007705A (es) 2017-01-11
TR201908392T4 (tr) 2019-07-22
CL2016001419A1 (es) 2017-01-20
CN105873932A (zh) 2016-08-17
KR102307053B1 (ko) 2021-10-01
ME03391B (me) 2020-01-20
CY1122521T1 (el) 2021-01-27
BR112016013572B1 (pt) 2023-03-21
RS58955B1 (sr) 2019-08-30
EP3088401A1 (en) 2016-11-02
JO3809B1 (ar) 2021-01-31
RU2016122867A3 (es) 2018-06-18
HUE044541T2 (hu) 2019-10-28
BR112016013572A2 (es) 2017-10-03
WO2015098853A1 (ja) 2015-07-02
AU2014371148B2 (en) 2018-08-09
PH12016501079A1 (en) 2016-07-11
KR20160094980A (ko) 2016-08-10
PL3088401T3 (pl) 2019-09-30
HK1222656A1 (zh) 2017-07-07
EP3088401B1 (en) 2019-03-06
NZ720718A (en) 2020-10-30
ES2728353T3 (es) 2019-10-23
US20150175615A1 (en) 2015-06-25
TW201609736A (zh) 2016-03-16
JP6085040B2 (ja) 2017-02-22
MY173946A (en) 2020-02-28
CA2932435A1 (en) 2015-07-02
CN105873932B (zh) 2017-11-24
RU2016122867A (ru) 2018-02-01
EP3088401A4 (en) 2017-06-28
DK3088401T3 (da) 2019-06-03
TWI681961B (zh) 2020-01-11
UA116923C2 (uk) 2018-05-25

Similar Documents

Publication Publication Date Title
AR098908A1 (es) Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida
AR089623A1 (es) Inhibidores de iap
PE20151606A1 (es) DERIVADOS DE NAFTIRIDINA UTILES COMO ANTAGONISTAS DE LA AvB6 INTEGRINA
UA113643C2 (xx) N-цикліламіди як нематоциди
EA201591457A8 (ru) Терапевтические соединения
AR090292A1 (es) Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan
AR093767A1 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona y profarmacos de estos
CR20130539A (es) Triazolopiridinas
MX2016014197A (es) 4-fenilpiperidinas sustituidas, su preparacion y uso.
PH12017500048A1 (en) Pyridone derivative having tetrahydropyranylmethyl group
AR097866A1 (es) Derivados de 4-azaindol
UA117490C2 (uk) Сполуки ізоіндоліну або ізохіноліну, спосіб їх одержання і фармацевтичні композиції, що їх містять
JP2015518492A5 (es)
JP2014521346A5 (es)
AR095523A1 (es) Derivados piridin-4-ilo
AR091770A1 (es) Indolcarbonitrilos moduladores selectivos de receptores androgenicos
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
CY1118079T1 (el) Μεθοδος παρασκευης του αλατος l-αργινινικης περινδοπριλης
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
AR098215A1 (es) Compuesto heterocíclico
AR091888A1 (es) Compuestos de urea y su uso como inhibidores de enzimas
AR101222A1 (es) Derivados de piridona
JP2013531183A5 (es)
ECSP13012365A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación,
DK3725810T3 (da) Kombinationterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer

Legal Events

Date Code Title Description
FG Grant, registration